How to Get Retatrutide in the UK

Published on: April 23, 2026

Medically reviewed by

Ashis Tandukar

Superintendent Pharmacist · Reg: GPhC No. 2084170

If you've been reading about retatrutide — the triple-agonist weight-loss drug producing around 24% body-weight reductions in trials — you've probably also noticed something strange. Every article talks about how impressive it is. Hardly any give you a straight answer about whether you can actually get it.

Here's the honest version. Retatrutide isn't approved. Not by the MHRA, not by the FDA, not by any regulator anywhere in the world. If you see a UK website offering retatrutide pens, they're selling you something unregulated — and it almost certainly isn't the medicine being tested by Eli Lilly. There are real pathways for people who want to try retatrutide safely. They just aren't what most people expect.

What retatrutide is, briefly

Retatrutide (Eli Lilly, development code LY3437943) is an investigational once-weekly injection that targets three hormones at once: GLP-1, GIP, and glucagon. Mounjaro (tirzepatide) hits two of those. Wegovy (semaglutide) hits one. Retatrutide hits all three — which is why you'll see it described as a triple agonist.

The Phase 2 data published in the New England Journal of Medicine in 2023 showed mean placebo-adjusted weight reductions of roughly 24% over 48 weeks at the highest 12mg dose. That's the headline number everyone is quoting. It's genuinely striking. It's also early — Phase 2 involved fewer than 350 participants on active treatment, and Phase 3 is where the efficacy and safety signals get confirmed at scale.

If you want a fuller breakdown of how the molecule works and what the trials actually measured, our companion piece on retatrutide's UK availability, safety and alternatives covers the mechanism in more detail.

The short answer: can you get retatrutide in the UK right now?

No — not through any legitimate channel outside a clinical trial.

Here's what that means in practice. The MHRA has not granted retatrutide a marketing authorisation. Without one, it can't be prescribed on the NHS, can't be prescribed privately by any UK doctor, and can't be dispensed by any GPhC-registered pharmacy. It also can't be supplied as an unlicensed "special." The specials pathway exists for patients whose specific clinical needs aren't met by licensed medicines — it isn't a workaround for drugs still in development.

Any UK website advertising retatrutide pens for home delivery is not selling a regulated medicine. Most are selling peptides synthesised by third-party labs and marketed as "research chemicals, not for human use." A smaller number mimic the branding of legitimate online pharmacies, which is more alarming, not less. Either way, the product itself isn't MHRA-approved and isn't covered by any of the normal safety nets.

Clinical trials: the only legal way to access retatrutide in the UK

The one genuine route to retatrutide in 2026 is enrolment in an authorised clinical trial. Lilly's Phase 3 programme — known as TRIUMPH — covers several studies in obesity, obesity with type 2 diabetes, obesity with knee osteoarthritis, and obesity with high cardiovascular risk. Some of these have active UK sites.

How to find a UK trial

Three starting points are worth your time:

• NIHR Be Part of Research (bepartofresearch.nihr.ac.uk) — the NHS's national registry of clinical studies. You can filter by condition (try "obesity" or "weight management") and by location, and register your interest directly.
• ISRCTN registry (isrctn.com) — an international clinical trial database with UK studies listed. Useful for cross-referencing sponsor-reported sites.
• Lilly Trial Information Center — Lilly's own portal for the TRIUMPH studies, which lists active recruiting sites and eligibility criteria. You can also contact the centre directly.

Your GP or an obesity-medicine specialist can also refer you to trial sites or signpost you to regional research networks.

What trial participation actually looks like

It isn't "free retatrutide." It's a structured medical study with real time commitments and real constraints. Broadly, expect:

• A screening visit to check eligibility — blood tests, an ECG, a BMI and comorbidity review
• Randomisation, meaning you might receive retatrutide, a comparator drug, or placebo. You won't know which, and neither will the study team looking after you.
• Regular in-person visits, typically every 4 weeks, for the duration of the trial
• Strict reporting of symptoms, dosing, weight, and other measures
• Exclusion criteria that usually include a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, severe gastroparesis, and pregnancy or breastfeeding

Most Phase 3 obesity trials run for 68-72 weeks of active treatment. You're committing serious time. And depending on the design, your chance of receiving the placebo rather than active drug can be anywhere from about 25% to 50%.

For many people, that's still worthwhile — both because the weight-loss potential is high if you are on active drug, and because trial participants are contributing to the evidence base the regulator will eventually use to decide whether retatrutide gets approved.

When will retatrutide actually be available in the UK?

The question we get asked most often. The honest answer is: probably not before 2027, and more realistically 2027 or 2028.

Here's the rough timeline. Lilly's Phase 3 obesity studies began recruiting in 2023 and are expected to complete primary data collection through 2026. From there, Lilly compiles the data and submits it to regulators — the FDA in the US, the EMA for Europe, and the MHRA for the UK. Standard regulatory review takes roughly 10-14 months, sometimes longer if the dossier is complex or additional data is requested.

Assuming approval, retatrutide would almost certainly appear through private UK online pharmacy services first, in the same way Mounjaro did after its 2023 UK launch. NHS access — if it happens at all — would follow a NICE technology appraisal, which took roughly a year for tirzepatide and is still being rolled out on a phased basis via specialist weight-management services.

A conservative expectation: private prescriptions possibly late 2027 or 2028, and NHS access some years after that, if and when NICE gives the green light.

What retatrutide is likely to cost

Any price is speculative until launch, but the current UK market sets a useful anchor:

Given retatrutide's positioning as a next-generation treatment with higher weight-loss efficacy in trials, pricing in line with or above Mounjaro's upper dose range is a reasonable guess. A private monthly cost of £200-£350 at launch wouldn't surprise us. The actual figure will depend on how Lilly prices the product globally, how UK pharmacies negotiate, and what competition looks like by then.

If cost is already a factor in your thinking, our Wegovy UK cost breakdown covers what you can currently access at a lower price point.

What about "retatrutide pens" and peptides sold online?

Most listings you'll find for retatrutide pens in the UK fall into one of three categories.

Research peptides. Sold under "research only, not for human use" labelling, often in 5mg, 10mg, 20mg, or 40mg strengths, and sometimes as pre-filled pens that look like licensed medicines. These are synthesised by unregulated labs — frequently in China, occasionally repackaged by EU resellers. The compound may or may not actually be retatrutide. Independent testing routinely turns up contamination with endotoxins, bacterial growth, or entirely different peptides. There's no batch-release testing to pharmaceutical standards and no legal recourse if something goes wrong.

Compounded copies. In the United States, some clinics have been offering compounded retatrutide. UK compounding is tightly regulated — and in any case, retatrutide isn't approved, so no UK compounding pharmacy can legitimately prepare it.

Outright scams. Sites that take your payment and either ship nothing or ship branded packaging containing saline, something else injectable, or a cheaper unrelated peptide.

The MHRA has issued repeated warnings about the risks of buying weight-loss injections from unauthorised online sources. UK hospital admissions after unregulated peptide use have included injection-site infections, hypoglycaemia from unknown dosing, and severe gastric stasis. These aren't rare, hypothetical harms. They happen regularly.

If you're tempted because the price is lower or access seems faster, it's worth being direct: the downside risk is serious, and you can't get the real drug this way. What you're buying is not retatrutide as Lilly makes it.

Licensed alternatives that work right now

If you want to start weight-loss treatment this month with a regulated medicine, two evidence-based options are available across UK online pharmacy services:

Mounjaro (tirzepatide)

Mounjaro is a weekly injection that targets GLP-1 and GIP — two of the three receptors retatrutide targets. Mean weight loss in the SURMOUNT-1 trial was 15-22.5% over 72 weeks, depending on dose.

• Starting dose: 2.5mg weekly
• Titrated up every 4 weeks if tolerated
• Maintenance doses: 5mg, 10mg, or 15mg weekly
• UK private cost: typically £140-£320/month

Our full Mounjaro dosage guide walks through titration schedules and what to expect at each dose.

Wegovy (semaglutide)

Wegovy targets GLP-1 alone and produces around 15% mean weight loss over 68 weeks in the STEP 1 trial.

• Starting dose: 0.25mg weekly
• Escalated monthly
• Maintenance dose: 2.4mg weekly
• UK private cost: typically £120-£220/month

Both medications are MHRA-approved, available on the NHS for eligible patients (see our guide to NHS eligibility for weight-loss injections), and dispensed by GPhC-registered pharmacies. You get proper pharmacovigilance, medical oversight, a known product, and a clear titration schedule.

For a wider overview of all currently licensed options, our UK weight-loss medication guide covers Mounjaro, Wegovy, and Orlistat side by side with costs and eligibility.

How to speak to a doctor about retatrutide

You don't need to keep quiet about your interest — clinicians working in obesity care hear these questions every day, and the worst outcome would be you not asking. A useful consultation tends to cover:

• Your treatment goals. What weight outcome are you working towards, and on what realistic timeline? Specific targets are easier to plan around than "I want to lose weight."
• Why retatrutide specifically? If it's the high trial numbers, a licensed option like Mounjaro may already meet your needs — it produces 15-22% weight loss in trials, which is meaningful. If you're drawn to a specific mechanism you've read about, it's reasonable to ask your clinician to put it in context.
• Trial eligibility. Ask your GP or obesity specialist whether they're aware of retatrutide trials recruiting in your region, or whether they'd be willing to refer you to a local research network.
• What to do in the meantime. Many patients who are interested in retatrutide start Mounjaro or Wegovy while they wait — both produce meaningful weight loss, both have established safety data, and you can review options again once newer treatments become available.

At Hey Slim, our clinicians see a lot of patients in this position. Interest in retatrutide is usually well-informed and overwhelmingly positive. We just try to be straight with people about what's possible this year and what isn't.

Medical disclaimer

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting any treatment.